TrialThe European respiratory journal2023

Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.

Julie Mankikian et al.PubMed ↗Publisher ↗

No numbers read from the abstract.